A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.
Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India
β Scribed by G Lakshmi; P.Sudershan Reddy; K.Ratna Kumar; N.V Bhavani; M Dayanand
- Book ID
- 117433811
- Publisher
- Elsevier Science
- Year
- 2000
- Tongue
- English
- Weight
- 169 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0264-410X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Six hundred and fifty New Zealand children from 2-12 years of age were vaccinated three times with 2 mcg intramuscular (IM) doses of Merck Sharp and Dohme plasma-derived hepatitis B vaccine (H-B-Vax), at 0, 1, and 6 months, and tested 2-3 months later for antibody to hepatitis B surface antigen (ant
## Abstract A multicentre, controlled, randomised, open, comparative trial including 839 healthy adult volunteers was carried out in order to compare the immunogenicity and reactogenicity of two vaccines against hepatitis A virus (HAV) during primary immunization and after booster injection. The fi